IMGN News and Press, ImmunoGen Inc. From 07/30/22

Image source: The Motley Fool. ImmunoGen (NASDAQ: IMGN) Q2 2022 Earnings Call Jul 29, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript

ImmunoGen, Inc. (IMGN) Q2 2022 Results Conference Call July 29, 2022 08:00 AM ET Company Participants Anabel Chan - Head of Investor Relations Mark Enyedy - President, CEO Anna Berkenblit - CMO Kristen Harrington-Smith - Chief Commercial Officer Susan Alt...

ImmunoGen ( NASDAQ: IMGN ) is trading ~7% down after the company posted lower-than-expected quarterly result, hurt by lower non-cash royalty revenue. Total revenues fell 16% Y/Y to $14.2M and missed estimates by $1.98M. Operating expenses for the ...

ImmunoGen press release ( NASDAQ: IMGN ): Q2 GAAP EPS of -$0.24 misses by $0.03 . Revenue of $14.2M (-16.2% Y/Y) misses by $1.98M . ImmunoGen had $373.9 million in cash and cash equivalents as of June 30, 2022, compared with $478.8 million as of December 31, 20...

BLA for Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer Accepted by FDA with Priority Review; PDUFA Date Set for November 28, 2022 Completed enrollment in the Confirmatory MIRASOL Study Presented Additional Efficacy and Safety Data for Mirvetuximab Monotherapy ...

ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q2 earnings results on Friday, July 29th, before market open. EPS Estimate is -$0.21 (-40.0% Y/Y) and the consensus Revenue Estimate is $16.18M (-4.5% Y/Y). For further details see: ImmunoGen Q2 Earnings Preview

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its second quarter 2022 operating results. ...

PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha expect...

Companies to Research Antibody-Drug Conjugates (ADCs) to Address Cancers of High Unmet Need Collaboration to Utilize ImmunoGen's ADC Linker-Payload Technology Directed to Targets Identified by OBT; Each Company May Select a Number of Preclinical Programs for Internal Developme...

Update 12:15pm: Updates shares, adds other potential names benefitting from the deal. Blueprint Medicines (NASDAQ:BPMC) rose 4% after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) c...